gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
creat bluematrix
last note avail click
cbio buy catalyst enter gene therapi
morn catalyst bioscienc gave indic enter
gene therapi gt space name plan poster eahad
showcas cb dalcinonacog alfa dalca part
transgen aav-bas gt catalyst announc present poster
entitl aav base hemophilia gene therapi mice use fix-cb
annual congress european associ
haemophilia alli disord eahad pragu februari
cb former name dalca compani phase i/ii
candid subcutan prophylact treatment hemophilia
note catalyst may enter gt space septemb
research took view fraction catalyst compound
vs fviia would need deliv achiev therapeut factor
level altern addit deliveri lower dose vector
due higher potenc catalyst-sourc transgen could help
mitig immunogen issu seen gt space
dalca would cours need fulli resolv question
immunogen part viabl gt construct recal
decemb research note seri updat dalca
immunogen profil highlight catalyst decemb
day among find although compani
previous report neutral antibodi nab patient cohort
phase i/ii studi dalca subsequ analysi show dalca
similar immunogen profil commercially-us benefix
dalca progress phase iib studi hemophilia
consequ therefor view phase iib dalca studi arbit
whether dalca transgen would valu note
given like standard-of-car set fix-padua gt given
fix-padua patent held uniqur buy chardan top pick
megacap hemophilia player look new exposur
make catalyst construct valuabl
cb provid preclin data dri age-rel macular
dalca initi phase iib studi hemophilia
marzaa present eahad phase ii data hemophilia a/b
inhibitor
dalca present eahad phase i/ii data hemophilia
marzaa end phase ii meet regul
hemophilia a/b inhibitor
marzaa file ind acquir hemophilia
pleas refer import disclosur inform regul analyst certif found page report
marzaa provid updat phase ii data isth hemophilia inhibitor
dalca present phase iib data nab analysi isth hemophilia
marzaa provid end phase ii data hemophilia inhibitor
decemb cbio buy buy weak dalca nab issu gain visibl
decemb cbio buy day dose nab isr marzaa
septemb cbio buy investor dinnerth market ascrib pii/iii marzaa
june cbio buy cb marzaa manufactur differ posit
june discount cash marzaa data upcom
march cbio buy posit ahead marzaa
februari cbio buy pt phase i/ii cb data hemophilia
june reiter buy cb phase i/ii support valuat potenti hemophilia
catalyst bioscienc cbio price target base valu cbio discount minimum
market cap credibl comp hemophilia space plan move back typic valuat methodolog
 dcf driven patient-bas market model disclosur catalyst asset
risk achiev target price
clinic risk clinic studi marzaa hemophilia inhibitor might fail show efficaci subcutan
subq prophylact therapi might gener safeti issu exampl thromboembol event might lead
format anti-drug antibodi creat efficaci and/or safeti risk moreov trial cb
hemophilia might fail show efficaci subq therapi due nab might gener safeti issu
regulatori risk certainti catalyst drug approv reimburs us elsewher
regulatori pathway prove complex and/or time consum anticip could materially-
neg impact project target price even assum result catalyst franchis achiev
target endpoint product obtain regulatori approv risk-adjust project price target
would expos downward revis
commerci risk potenti catalyst indic may larg project highlight
competit hemophilia inhibitor roch unrat alnylam buy novo nordisk unrat shire
unrat highlight competit hemophilia unrat sanofi unrat novo nordisk shire
behr unrat alnylam neutral uniqur buy sangamo unrat freelin
therapeut privat addit catalyst build sale market medic affair infrastructur
us possibl global region
financ risk catalyst potenti need rais addit capit fund clinic trial perhap via equiti
financ reach profit potenti result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
catalyst bioscienc found went public august merger targacept catalyst
focus therapi treatment hemophilia develop engin recombin clot factor
design subcutan administr compani lead asset engin activ factor vii marzaa
treatment hemophilia inhibitor phase ii/iii trial second asset engin factor ix dalca
treatment hemophilia phase i/ii trial catalyst also engin activ factor treatment
page
coagul disord program treatment renal delay graft function cardiovascular diseas
dri catalyst headquart south san francisco california
page
rate price target histori catalyst bioscienc inc cbio
creat bluematrix
rate price target histori inc
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori uniqur qure
creat bluematrix
distribut ratings/ib servic
analyst certif analyst respons cover secur report certifi view
express research report accur reflect person view compani secur analyst
respons cover secur report certifi part compens directli
indirectli relat specif recommend view contain research report
